Back to Journals » Therapeutics and Clinical Risk Management » Volume 3 » Issue 5

Naltrexone long-acting formulation in the treatment of alcohol dependence

Authors Bankole A Johnson

Published 15 November 2007 Volume 2007:3(5) Pages 741—749

Bankole A Johnson

Department of Psychiatry and Neurobehavioral Sciences, University of Virginia, Charlottesville, VA, USA

Abstract: While oral naltrexone has a demonstrated ability to decrease alcohol reinforcement, it also has pharmacotherapeutic limitations, such as a small treatment effect size, adverse events, and plasma level fluctuations. The pharmacokinetic profile of naltrexone could be enhanced by intramuscular administration, which would sustain its release over several weeks and keep plasma levels relatively constant, ie, low enough to minimize side effects but high enough to reduce drinking. Vivitrex®/Vivitrol® and Naltrel® are injectable naltrexone depot formulations that have been tested as possible medications for treating alcohol dependence. Their adverse-event profiles appear to be less severe than that of oral naltrexone. Vivitrex®/Vivitrol® has demonstrated efficacy at decreasing heavy drinking among alcohol-dependent males. Naltrel® helped to promote abstinence and decrease the incidence of relapse in two samples of alcohol-dependent subjects. The data on a third formulation, Depotrex®, are still limited. All three formulations require further study of their efficacy.

Keywords: alcohol dependence, depot, Depotrex®, Naltrel®, naltrexone, Vivitrex®, Vivitrol®

Download Article [PDF] 

Readers of this article also read:

Ultraviolet light and laser irradiation enhances the antibacterial activity of glucosamine-functionalized gold nanoparticles

Govindaraju S, Ramasamy M, Baskaran R, Ahn SJ, Yun KS

International Journal of Nanomedicine 2015, 10:67-78

Published Date: 25 August 2015

The impact of cardiac and noncardiac comorbidities on the short-term outcomes of patients hospitalized with acute myocardial infarction: a population-based perspective

Chen HY, Saczynski JS, McManus DD, Lessard D, Yarzebski J, Lapane KL, Gore JM, Goldberg RJ

Clinical Epidemiology 2013, 5:439-448

Published Date: 7 November 2013

Causal diagrams and the logic of matched case-control studies

Shahar E, Shahar DJ

Clinical Epidemiology 2012, 4:137-144

Published Date: 15 May 2012

Takotsubo cardiomyopathy in two men receiving bevacizumab for metastatic cancer

Thérèse H Franco, Ahmed Khan, Vishal Joshi, Beje Thomas

Therapeutics and Clinical Risk Management 2008, 4:1367-1370

Published Date: 5 December 2008

Spontaneous bacterial peritonitis: How to deal with this life-threatening cirrhosis complication?

Tarsila CR Ribeiro, Julio MF Chebli, Mario Kondo, Pedro Duarte Gaburri, Liliana Andrade Chebli, Ana Cristina Amaral Feldner

Therapeutics and Clinical Risk Management 2008, 4:919-925

Published Date: 10 October 2008

Treating refractory leukemias in childhood, role of clofarabine

Theresa M Harned, Paul S Gaynon

Therapeutics and Clinical Risk Management 2008, 4:327-336

Published Date: 11 April 2008

Long-term safety and effectiveness of sildenafil citrate in men with erectile dysfunction

James G McMurray, Robert A Feldman, Stephen M Auerbach, Herb DeRiesthal, Neal Wilson et al

Therapeutics and Clinical Risk Management 2007, 3:975-981

Published Date: 15 January 2008

Montelukast in the management of allergic rhinitis

Jaime A Lagos, Gailen D Marshall

Therapeutics and Clinical Risk Management 2007, 3:327-332

Published Date: 15 May 2007

Optimal timing for antihypertensive dosing: focus on valsartan

Ramón C Hermida, Diana E Ayala, Carlos Calvo

Therapeutics and Clinical Risk Management 2007, 3:119-131

Published Date: 15 March 2007